Tessera Therapeutics
Yaser Heshmati, Ph.D., is a Senior Scientist at Tessera Therapeutics, where responsibilities include mRNA-LNP mediated Gene Rewriting in hematopoietic stem cells for sickle cell disease, as well as conducting hematology assays for gene correction validation. Prior experience includes roles as a Postdoctoral Researcher at both Boston Children's Hospital and Harvard Medical School, focusing on hematology/oncology and the discovery of therapeutic targets through genome-wide CRISPR/Cas9 screening. Additionally, Yaser worked as a Postdoctoral Researcher at Karolinska University Hospital in Clinical Genetics and Hematology. Academic credentials include a Ph.D. in Medical Genetics from Karolinska Institutet, an MSc in Human Genetics from the University of Social Welfare and Rehabilitation Sciences in Tehran, and a BSc in Molecular Genetics from Shahid Chamran University of Ahvaz.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.